CAR T-Cell Therapy for Relapsed/Refractory CLL
2 vistas
• 07/14/23
0
0
Empotrar
administrator
Suscriptores
The panelists provide insight on the use of chimeric antigen receptor T-cell therapy for chronic lymphocytic leukemia and the TRANSCEND CLL-004 trial of liso-cel (JCAR017) in relapsed/refractory disease.
Mostrar más
Comentarios de Facebook
SORT BY-
Top Comentarios
-
Últimos comentarios